Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$312.01M+76.9%
Viatris logo
ViatrisVTRS
$1.81B+139%
AptarGroup logo
AptarGroupATR
$224.95M+78.8%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$24.32M-39.0%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$197.66M+234%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's cash & equivalents?
Amphastar Pharmaceuticals (AMPH) reported cash & equivalents of $170.94M in Q1 2026.
How has Amphastar Pharmaceuticals's cash & equivalents changed year-over-year?
Amphastar Pharmaceuticals's cash & equivalents decreased by 6.5% year-over-year, from $182.78M to $170.94M.
What is the long-term trend for Amphastar Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's cash & equivalents has grown at a 12.9% compound annual growth rate (CAGR), from $92.64M to $170.18M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.